X0306 4 2018-10-12 0 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001450485 Lurker Nancy C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 1 1 0 0 President & CEO Common Stock 2018-10-12 4 A 0 76667 0.00 A 211700 D On October 12, 2018 (the "FDA Approval Date"), the U.S. Food and Drug Administration approved EyePoint Pharmaceutical Inc.'s (the "Company") new drug application for YUTIQ for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. As a result, 38,334 shares representing a previously granted performance stock unit award vested on that date. An additional 38,333 shares from this award will vest on the first anniversary of the FDA Approval Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date. /s/ John Mercer, Attorney-in-Fact 2018-10-16